Tumor necrosis factor inhibitors are reported to have efficacy in treating pulmonary and CNS sarcoidosis as well as other inflammatory disorders such as Behçet disease.34,35,36 We identified 8 patients with de novo neurosarcoidosis, of which 7 had previous TNF inhibitor exposure. The gene discussed is TNF; the disease is neurosarcoidosis.